You just read:

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

News provided by

Camurus AB

Nov 14, 2016, 02:00 ET